ANNOUNCES PUBLICATION OF POSITIVE PHASE 2 DATA WITH CPX-351 IN ACUTE MYELOID
May 27, 2014 (GLOBE NEWSWIRE via COMTEX) -- Celator Pharmaceuticals, Inc.
announced the publication of the Phase 2 study evaluating CPX-351 in newly
diagnosed older patients with acute myeloid leukemia (AML) in Blood, the official
journal of the American Society of Hematology. The study manuscript entitled
"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin,
vs cytarabine/daunorubicin in older adults with untreated AML" appears in the May 22, 2014 issue.
These data, along with results from the Phase 2 study of CPX-351 in patients with
AML in first relapse, support Celator's currently-enrolling Phase 3 study of CPX-351
as a first-line therapy in older patients with high-risk (secondary) AML,
which is being conducted in partnership with The Leukemia & Lymphoma Society®.
"Acute myeloid leukemia is an aggressive blood cancer with a high unmet need, particularly
in older patients," said Jeffrey Lancet M.D., Lead Investigator and Section Chief of Leukemia
at the H. Lee Moffitt Cancer Center and Research Institute. "AML patients treated with CPX-351
had a higher likelihood of remission, without evidence of increased early mortality, than
patients treated with standard chemotherapy. In addition, CPX-351 led to longer survival
in the large subset of patients whose AML arose out of a previously diagnosed hematologic
disorder or a history of prior cytotoxic treatment, commonly referred to as secondary AML."
This randomized, controlled, Phase 2 study evaluated 126 patients, aged 60-75 years, from 18
clinical centers in the U.S. and Canada, with newly diagnosed, pathologically confirmed AML.
Patients were randomized 2:1 to receive first-line CPX-351 (100 u/m2; days 1, 3, and 5 by 90
minute infusion) or the 7+3 regimen (cytarabine 100 mg/m2/day by continuous infusion for 7 days
and daunorubicin 60 mg/m2 on days 1, 2, and 3). The primary endpoint for the study was complete
response (CR + CRi) and secondary endpoints included CR+CRi duration, event-free survival and
Results showed that CPX-351 treatment was associated with higher complete response rate
(66.7% vs. 51.2%; P = 0.07), prolonged event-free survival (median 6.5 vs. 2.0 months) and
overall survival (median 14.7 vs. 12.9 months). Ten patients with persistent AML after treatment
with 7+3 crossed over to receive CPX-351 as salvage therapy with four achieving response
(3 CR + 1 CRi). All four responders survived more than one year and this potentially
confounds interpretation of the overall survival data.
A planned analysis of secondary AML patients (patients with a prior antecedent hematologic
disorder or history of prior cytotoxic treatment) showed an improved response rate (57.6% vs
31.6%, P=0.06), prolonged event-free survival (median 4.5 vs. 1.3 months, HR=0.59, P=0.08) as
well as overall survival (median 12.1 vs. 6.1 months, HR=0.46, P=0.01). The overall survival
benefit in this population was statistically significant.
Treatment with CPX-351 was associated with well-characterized and manageable adverse events.
Recovery from cytopenias was longer following CPX-351 (median days to anc ≥1000:36 vs. 32)
(platelets >100k:37 vs. 28) with more grade 3-4 infections but without an increase in
infection-related deaths (3.5% vs. 7.3%) or 60-day mortality (4.7% vs. 14.6%), indicating
"We are very pleased with the results and insights this study offered," said Arthur C. Louie,
Chief Medical Officer of Celator. "These data suggest an enhanced clinical benefit of CPX-351
over the current standard of care, known as the 7+3 regimen, and we hope to further validate
these findings with our Phase 3 study, with initial data expected in the second quarter of 2015."
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:floxuridine), and hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. For more information, please visit the company's website at www.celatorpharma.com
. Information on ongoing trials is available at www.clinicaltrials.gov
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will" "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, our expectations regarding our development plans for and the potential efficacy, therapeutic potential of our drug candidates, our expectations regarding the trading of our common stock and other matters that could affect the availability or commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Celator's Form 10-K for the year ended December 31, 2012 and other filings by the company with the U.S. Securities and Exchange Commission.
Mike Beyer, Sam Brown, Inc.
773 463-4211, email@example.com
ProActive Capital Adam Holdsworth, 212 362-1200